ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.54, $0.20 worse than the analyst estimate of $0.74. Revenue for the quarter came in at $60.9 million versus the consensus estimate of $56.3 million.

GUIDANCE:

ANI Pharma sees FY2022 revenue of $260-275 million, versus the consensus of $301.6 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.